Pharmacotherapy causing weight gain and metabolic alteration in those with obesity and obesity-related conditions: A review

Ann N Y Acad Sci. 2024 Mar;1533(1):145-155. doi: 10.1111/nyas.15112. Epub 2024 Feb 22.

Abstract

This review aims to summarize pharmacological interventions that may affect adiposity and metabolic equilibrium in individuals with obesity. Pharmacological therapy is frequently used to treat medical conditions that are both directly related to obesity (such as hypertension and type 2 diabetes) and indirectly related to obesity (such as asthma, insomnia, and type 1 diabetes). This pharmacological therapy may result in weight gain and alterations in the metabolic profile. Many medication classes are implicated in the pharmacologic causes of weight gain, including antipsychotics, glucocorticoids, beta-adrenergic blockers, tricyclic antidepressants, antihistamines, insulin, neuropathic agents, sleep agents, and steroids. This article describes the mechanisms of action and pathways of pharmacological interventions causing obesity.

Keywords: metabolism; obesity; obesity comorbidities; pharmacotherapy; weight gain.

Publication types

  • Review

MeSH terms

  • Antipsychotic Agents* / therapeutic use
  • Diabetes Mellitus, Type 2* / drug therapy
  • Humans
  • Insulin
  • Obesity / drug therapy
  • Weight Gain

Substances

  • Antipsychotic Agents
  • Insulin